OncoMatch/Clinical Trials/NCT05879055

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Is NCT05879055 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PM8002 and FOLFIRI for neuroendocrine neoplasm.

Phase 2RecruitingBiotheus Inc.NCT05879055Data as of May 2026

Treatment: PM8002 · FOLFIRI — PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: platinum-based chemotherapy — first-line

Lab requirements

Blood counts

Adequate organ function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify